Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use as a Steroid Sparing Agent
The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.
• Age ≥ 18 years
• Ability to sign informed consent document
• Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
• Patients with a diagnosis of CTCL who have intractable pruritis
• Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief
• Patients on chemo/immunotherapy with drug induced rash